<!doctype html><html><head><meta charset=utf-8><title>CIS (MS) reduced 36% by two capsules of 50,000 IU of Vitamin D taken biweekly – RCT</title>
<link rel=stylesheet href="/css/main.css?v=1748384341"><link rel=stylesheet href="/css/pagination.css?v=1748384341"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src=https://unpkg.com/lunr/lunr.js></script><script src=https://cdn.jsdelivr.net/npm/pako@2.1.0/dist/pako.min.js></script><script src="/js/search.js?v=1748384341"></script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><h1>CIS (MS) reduced 36% by two capsules of 50,000 IU of Vitamin D taken biweekly – RCT</h1><time>March 10, 2025</time><nav id=TableOfContents><ul><li><ul><li><ul><li><a href=#high-dose-vitamin-d-in-clinically-isolated-syndrome-typical-of-multiple-sclerosis--the-d-lay-ms-randomized-clinical-trial>High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis – The D-Lay MS Randomized Clinical Trial</a></li><li><a href=#vitamindwiki-a-hrefpostscoimbra-high-dose-vitamin-d-protocol-many-studies-stylecolor-red-text-decoration-underline-titlethis-postcategory-does-not-exist-yet-coimbra-high-dose-vitamin-d-protocol---many-studiescoimbra-high-dose-vitamin-d-protocol---many-studiesa>VitaminDWiki <a href=/posts/coimbra-high-dose-vitamin-d-protocol-many-studies style=color:red;text-decoration:underline title="This post/category does not exist yet: Coimbra high-dose vitamin D protocol - many studies">Coimbra high-dose vitamin D protocol - many studies</a></a></li></ul></li></ul></li></ul></nav><hr><h4 id=high-dose-vitamin-d-in-clinically-isolated-syndrome-typical-of-multiple-sclerosis--the-d-lay-ms-randomized-clinical-trial>High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis – The D-Lay MS Randomized Clinical Trial</h4><p>JAMA. March 10, 2025. doi:10.1001/jama.2025.1604 PDF behind paywall</p><img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/cis-100k.webp alt=image width=600>
<img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/ms-cis-rct.webp alt=image width=900><p>Importance Vitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting.</p><p>Objective To evaluate the efficacy of high-dose cholecalciferol as monotherapy in reducing disease activity in patients with clinically isolated syndrome (CIS) typical for MS.</p><p>Design, Setting, and Participants The D-Lay MS trial was a parallel, double-blind, randomized placebo-controlled clinical trial in 36 MS centers in France. Patients were enrolled from July 2013 to December 2020 (final follow-up on January 18, 2023). Untreated patients with CIS aged 18 to 55 years with CIS duration less than 90 days, serum vitamin D concentration less than 100 nmol/L, and diagnostic magnetic resonance imaging (MRI) meeting 2010 criteria for dissemination in space or 2 or more lesions and presence of oligoclonal bands were recruited.</p><p>Intervention Patients were randomized 1:1 to receive oral cholecalciferol 100 000 IU (n = 163) or placebo (n = 153) every 2 weeks for 24 months.</p><p>Main Outcomes and Measures The primary outcome measure was disease activity, defined as occurrence of a relapse and/or MRI activity (new and/or contrast-enhancing lesions) over 24 months of follow-up, also analyzed as separate secondary outcomes.</p><p>Results Of the 316 participants enrolled and randomized (median <span>[IQR]</span> age, 34 <span>[28-42]</span> years; 70% women), the primary analysis included 303 patients (95.9%) who took at least 1 dose of the study drug and 288 (91.1%) ultimately completed the 24-month trial.</p><p>Disease activity</p><ul><li><p>was observed in 94 patients (60.3%) in the vitamin D group and 109 patients (74.1%) in the placebo group ( <strong>hazard ratio <span>[HR]</span>, 0.66</strong> <span>[95% CI, 0.50-0.87]</span>; P = .004), and</p></li><li><p>median time to disease activity was longer in the vitamin D group (432 vs 224 days; log-rank P = .003).</p></li></ul><p>All 3 secondary MRI outcomes reported significant differences favoring the vitamin D group vs the placebo group:</p><ul><li><p>MRI activity (89 patients <span>[57.1%]</span> vs 96 patients <span>[65.3%]</span>; HR, 0.71 <span>[95% CI, 0.53-0.95]</span>; P = .02),</p></li><li><p>new lesions (72 patients <span>[46.2%]</span> vs 87 patients <span>[59.2%]</span>; HR, 0.61 <span>[95% CI, 0.44-0.84]</span>; P = .003), and</p></li><li><p>contrast-enhancing lesions (29 patients <span>[18.6%]</span> vs 50 patients <span>[34.0%]</span>; HR, 0.47 <span>[95% CI, 0.30-0.75]</span>; P = .001).</p></li></ul><p>All 10 secondary clinical outcomes showed no significant difference, including</p><ul><li>relapse, which occurred in 28 patients (17.9%) in the vitamin D group vs 32 (21.8%) in the placebo group (HR, 0.69 <span>[95% CI, 0.42-1.16]</span>; P = .16). Results were similar in a subset of 247 patients meeting updated 2017 diagnostic criteria for relapsing-remitting MS at treatment initiation.</li></ul><p>Severe adverse events occurred in 17 patients in the vitamin D group and 13 in the placebo group, none of which were related to cholecalciferol.</p><p>Conclusions and Relevance Oral cholecalciferol 100 000 IU every 2 weeks significantly reduced disease activity in CIS and early relapsing-remitting MS. These results warrant further investigation, including the potential role of pulse high-dose vitamin D as add-on therapy.</p><p>Trial Registration ClinicalTrials.gov Identifier: NCT01817166</p><hr><h4 id=vitamindwiki-a-hrefpostscoimbra-high-dose-vitamin-d-protocol-many-studies-stylecolor-red-text-decoration-underline-titlethis-postcategory-does-not-exist-yet-coimbra-high-dose-vitamin-d-protocol---many-studiescoimbra-high-dose-vitamin-d-protocol---many-studiesa>VitaminDWiki <a href=/posts/coimbra-high-dose-vitamin-d-protocol-many-studies style=color:red;text-decoration:underline title="This post/category does not exist yet: Coimbra high-dose vitamin D protocol - many studies">Coimbra high-dose vitamin D protocol - many studies</a></h4><p><strong>About 10X more Vitamin D often &ldquo;cured&rsquo; Multiple Sclerosis during the previous 15 years</strong></p></article></div></div><script src="/js/lightspa.js?v=1748384341"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1748384341",indexUrl:"/search/search_index.json.gz?v=1748384341"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/toc-sanitizer.js?v=1748384341"></script><script src="/js/search-results-panel.js?v=1748384341"></script><script src="/js/tiki-redirects.js?v=1748384341"></script></body></html>